Cel Sci Corp Stock Today
| CVM Stock | USD 0.69 0.05 6.76% |
Performance0 of 100
| Odds Of DistressOver 83
|
CEL SCI is selling at 0.69 as of the 16th of December 2024; that is 6.76% down since the beginning of the trading day. The stock's lowest day price was 0.69. CEL SCI has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 22nd of December 2023 and ending today, the 16th of December 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 1st of January 1987 | Category Healthcare | Classification Health Care |
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company was incorporated in 1983 and is headquartered in Vienna, Virginia. Cel-Sci Corp operates under Biotechnology classification in the United States and is traded on AMEX Exchange.. The company has 63.81 M outstanding shares of which 4.43 M shares are currently shorted by investors with about 18.05 days to cover. More on CEL SCI Corp
Moving together with CEL Stock
Moving against CEL Stock
CEL Stock Highlights
| CEO | Geert Kersten | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Old Names | [CVR Medical Corp, CROWN MEDIA HLDG-A - Frankfurt Stock Exchang] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsCEL SCI can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand CEL SCI's financial leverage. It provides some insight into what part of CEL SCI's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
CEL SCI Corp (CVM) is traded on NYSE MKT Exchange in USA. It is located in 8229 Boone Boulevard, Vienna, VA, United States, 22182 and employs 10 people. CEL SCI is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a total capitalization of 44.71 M. CEL SCI Corp runs under Biotechnology sector within Health Care industry. The entity has 63.81 M outstanding shares of which 4.43 M shares are currently shorted by investors with about 18.05 days to cover.
CEL SCI Corp has about 22.67 M in cash with (22.85 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.65.
Check CEL SCI Probability Of Bankruptcy
Ownership AllocationCEL SCI holds a total of 63.81 Million outstanding shares. Almost 86.63 percent of CEL SCI outstanding shares are held by general public with 2.91 (percent) owned by insiders and only 10.46 % by other corporate entities. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check CEL Ownership Details
CEL SCI Historical Income Statement
CEL Stock Against Markets
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CEL SCI Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CEL SCI. If investors know CEL will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CEL SCI listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.52) | Revenue Per Share 0.001 | Quarterly Revenue Growth (0.63) | Return On Assets (0.61) | Return On Equity (2.50) |
The market value of CEL SCI Corp is measured differently than its book value, which is the value of CEL that is recorded on the company's balance sheet. Investors also form their own opinion of CEL SCI's value that differs from its market value or its book value, called intrinsic value, which is CEL SCI's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CEL SCI's market value can be influenced by many factors that don't directly affect CEL SCI's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CEL SCI's value and its price as these two are different measures arrived at by different means. Investors typically determine if CEL SCI is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CEL SCI's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.